© 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Morphine sulphate Taj API

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Morphine sulphate Manufacturers in India Suppliers Morphine sulphate Exporters Distributors Morphine sulphate api active pharmaceuticals ingredients Morphine sulphate manufacturers Side Effects bulk drugs raw material Morphine sulphate companies Side Effects Importers Morphine sulphate Morphine sulphate Exporters Morphine sulphate exporters FDA Morphine sulphate DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Morphine sulphate manufacturing pharmaceutical drugs pharmaceutical intermediates Morphine sulphate pharmaceutical chemicals pharmaceutical raw materials Morphine sulphate active pharmaceutical ingredients Morphine sulphate committee active pharmaceutical ingredients manufacturer Morphine sulphate Active Pharmaceutical Ingredients manufacturer Morphine sulphate exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Morphine sulphate, Morphine sulphate manufacturer India, Morphine sulphate product, Morphine sulphate products, Api preparation, Certificate of Analysis API manufacturer product, Morphine sulphate anti ulcer product, Certificate of Origin COA Morphine sulphate COS Morphine sulphate, pharmaceutical generic, pharmaceutical drug, medical, Morphine sulphate pharma healthcare, pharma patents, contract MSDS manufacturing Trader Morphine sulphate pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Morphine sulphate expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Morphine sulphate DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Morphine sulphate ingredients, api, HIV Morphine sulphate, tablets, capsules, syrup & protein Morphine sulphate powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Morphine sulphate gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Morphine sulphate WHO, UKMHRA Approval

   PRODUCT LIST
   Home
   API >>>
   Pharmaceuticals API List
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 
More API manufacturing at Taj

Oseltamivir Phosphate  

Phenyl Propanolamine

Phenylephrine

Etafedrine
Theophylline
Tramadol
Methylphenidate
Morphine HCl
Morphine sulphate
Ephedrine (EPH)
Pseudoephedrine hydrochloride
Codeine base
Codeine phosphate hemihydrate
Zolpidem Tartrate
Caffeine

DRUG DESCRIPTION

morphine are essentially those observed with other  analgesics


 


 


 





 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
HOME >> API >> Morphine Sulphate

Morphine sulphate

Morphine sulphate Chemical data


     Morphine sulphate Cas No. 64-31-3


Morphine sulphate Formula C17H19NO3

Morphine sulphate
pdf api

Chemical data

Formula C17H19NO3

Mol. mass 285.34

Pharmacokinetic data

Bioavailability ~25% (oral); 100% (IV);
Protein binding 30–40%
Metabolism Hepatic 90%
Half life 2–3 h
Excretion Renal 90%, biliary 10%

DRUG DESCRIPTION

Morphine sulphate Cas No. 64-31-3


Morphine can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing Morphine sulphate in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Chemically, morphine sulfate is 7,8-didehydro-4,5α-epoxy-17-methylmorphinan-3,6α-diol sulfate (2:1) (salt) pentahydrate

Morphine sulphate Tablets are opiate analgesics supplied in 15, 30, 60, 100 and 200 mg tablet strengths. The tablet strengths describe the amount of morphine per tablet as the pentahydrated sulfate salt (morphine sulfate, USP). Morphine sulphate Controlled-release Tablets 15 mg, 30 mg, 60 mg, 100 mg, and 200 mg contain the following inactive ingredients: cetostearyl alcohol, hydroxyethyl cellulose, hypromellose, magnesium stearate, polyethylene glycol, talc and titanium dioxide.

DOSAGE
Morphine sulphate Cas No. 64-31-3


Morphine Sulphate DOSAGEThe dosage is based on your medical condition and response to treatment. Do not increase your dose, take the medication more frequently, or take it for a longer time than prescribed. Properly stop the medication when so directed. You may also take quick-acting narcotic pain medications for sudden (breakthrough) pain if so directed by your doctor. Also follow your doctor's or pharmacist's instructions for safely using non-narcotic pain relievers (such as naproxen, ibuprofen). If you have been using other long-acting narcotic pain medications or narcotic patches regularly, check with your doctor or pharmacist because you may need to stop using them before you start using this medication. If you are currently using a narcotic patch (such as fentanyl), the effects may continue after it is removed. Ask your doctor or pharmacist when it will be safe to start taking this medication (usually 18 hours after removing the patch).

Take this medication by mouth with or without food, usually 2 or 3 times daily (every 8 or 12 hours) or as directed by your doctor. If you have nausea, it may help to take this drug with food. Consult your doctor or pharmacist about other ways to decrease nausea (such as taking antihistamines, lying down for 1 to 2 hours with as little head movement as possible).

SIDE EFFECTS
Morphine sulphate Cas No. 64-31-3


The adverse reactions caused by morphine are essentially those observed with other  analgesics. They include the following major hazards: respiratory depression, apnea, and to a lesser degree, circulatory depression, respiratory arrest, shock, and cardiac arrest.
Most Frequently Observed

Constipation, lightheadedness, dizziness, sedation, nausea, vomiting, sweating, dysphoria, and euphoria.

Some of these effects seem to be more prominent in ambulatory patients and in those not experiencing severe pain. Some adverse reactions in ambulatory patients may be alleviated if the patient lies down.
Less Frequently Observed Reactions

Central Nervous System: Weakness, headache, agitation, tremor, uncoordinated muscle movements, seizure, alterations of mood (nervousness, apprehension, depression, floating feelings), dreams, muscle rigidity, transient hallucinations and disorientation, visual disturbances, insomnia, increased intracranial pressure

Gastrointestinal: Dry mouth, biliary tract spasm, laryngospasm, anorexia, diarrhea, cramps, taste alteration, constipation, ileus, intestinal obstruction, dyspepsia, increases in hepatic enzymes

Cardiovascular: Flushing of the face, chills, tachycardia, bradycardia, palpitation, faintness, syncope, hypotension, hypertension

Genitourinary: Urine retention or hesitance, amenorrhea, reduced libido and/or potency

Dermatologic: Pruritus, urticaria, other skin rashes, edema, diaphoresis

Other: Antidiuretic effect, paresthesia, bronchospasm, muscle tremor, blurred vision, nystagmus, diplopia, miosis, anaphylaxis

PRECAUTIONS
Morphine sulphate Cas No. 64-31-3


Morphine sulphate Tablets are a controlled-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. Morphine sulphate does not release morphine continuously over the course of a dosing interval. The administration of single doses of Morphine sulphate on a q12h dosing schedule will result in higher peak and lower trough plasma levels than those that occur when an identical daily dose of morphine is administered using conventional oral formulations on a q4h regimen. The clinical significance of greater fluctuations in morphine plasma level has not been systematically evaluated.

Selection of patients for treatment with Morphine sulphate® should be governed by the same principles that apply to the use of morphine or other potent opioid analgesics. Specifically, the increased risks associated with its use in the following populations should be considered: the elderly or debilitated and those with severe impairment of hepatic, pulmonary, or renal function; myxedema or hypothyroidism; adrenocortical insufficiency (e.g., Addison's Disease); CNS depression or coma; toxic psychosis; prostatic hypertrophy or urethral stricture; acute alcoholism; delirium tremens; kyphoscoliosis or inability to swallow.

The administration of morphine, like all opioid analgesics, may obscure the diagnosis or clinical course in patients with acute abdominal conditions.

Morphine may aggravate convulsions in patients with convulsive disorders, and all opioids may induce or aggravate seizures in some clinical settings.

Morphine may aggravate convulsions in patients with convulsive disorders,

 
   
Information Associated with Product:
INTERACTION
CONSUMER INFORMATION
 
 
PDF DOWNLOAD WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Note: These API/ chemicals are designated as those that are used in the manufacture of the controlled substances and are important to the manufacture of the substances. For any (Control Substance) products Import and Export *** subjected to your country government laws /control substance ACT.
Note /Government Notification: These chemicals are designated as those that are used in the manufacture of the controlled substances and are important to the manufacture of the substances. For any (Control Substance) products Import and Export *** subjected to your country government laws /control substance ACT.
Information:  The information on this web page is provided to help you to work safely, but it is intended to be an overview of hazards, not a replacement for a full Material Safety Data Sheet (MSDS). MSDS forms can be downloaded from the web sites of many chemical suppliers. ,also that the information on the PTCL Safety web site, where this page was hosted, has been copied onto many other sites, often without permission. If you have any doubts about the veracity of the information that you are viewing, or have any queries, please check the URL that your web browser displays for this page. If the URL begins "www.tajapi.com/www/Denatonium Benzoate.htm/" the page is maintained by the Safety Officer in Physical Chemistry at Oxford University. If not, this page is a copy made by some other person and we have no responsibility for it.
The Controlled Substances Act (CSA) was enacted into law by the Congress of the United States as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970.[1] The CSA is the federal U.S. drug policy under which the manufacture, importation, possession, use and distribution of certain substances is regulated. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs
Taj Pharmaceuticals API Logo

 

Morphine sulphate

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
© 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited  products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.